Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: [ 18F]F-AraG PET
Eligibility
Inclusion Criteria:
- Age ≥ 18 years old
- Histologically confirmed aggressive B cell NHL including the following types defined
by WHO 2008:
- DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma;
DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of
the elderly; OR
- primary mediastinal (thymic) large B cell lymphoma
- transformation of follicular lymphoma, marginal zone lymphoma or chronic
lymphocytic leukemia to DLBCL will also be included
- Measurable disease by PET imaging (as defined by Cheson (2014)), that meets all the
following criteria:
- At least one measureable lesion away from head & neck, liver, kidneys, GI tract
and bladder
- At least one biopsy-accessible lesion or lymph node.
- Express willingness to undergo low risk FNA or core biopsy of subcutaneous accessible
lesion or lymph node.
- Scheduled to receive commercial or research CAR T cell therapy with axicabtagene
ciloleucel (Yescarta ®) as part of anticancer therapy.
- Adequate renal and hepatic function, defined as:
1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min or Cr < 1.6
mg/dL
2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5x
upper limit of normal (ULN)
3. Total bilirubin ≤ 1.5 mg/dL, except in cases of Gilbert's syndrome
- Able to give informed consent. Subjects unable to give informed consent will not be
eligible for this study
Exclusion Criteria:
- Women who are pregnant or breastfeeding.
- Subjects with significant GI disease involvement by PET imaging
- In the investigator's judgment, have any medical condition likely to interfere with
assessment of safety or efficacy, be unable to tolerate additional radiation, or be
unlikely to complete all protocol-required visits and procedures.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Maria Iglesias
I'm interested
Psoriasis Clinical Trials
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: [ 18F]F-AraG PET
Eligibility
Inclusion Criteria:
- Age ≥ 18 years old
- Histologically confirmed aggressive B cell NHL including the following types defined
by WHO 2008:
- DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma;
DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of
the elderly; OR
- primary mediastinal (thymic) large B cell lymphoma
- transformation of follicular lymphoma, marginal zone lymphoma or chronic
lymphocytic leukemia to DLBCL will also be included
- Measurable disease by PET imaging (as defined by Cheson (2014)), that meets all the
following criteria:
- At least one measureable lesion away from head & neck, liver, kidneys, GI tract
and bladder
- At least one biopsy-accessible lesion or lymph node.
- Express willingness to undergo low risk FNA or core biopsy of subcutaneous accessible
lesion or lymph node.
- Scheduled to receive commercial or research CAR T cell therapy with axicabtagene
ciloleucel (Yescarta ®) as part of anticancer therapy.
- Adequate renal and hepatic function, defined as:
1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min or Cr < 1.6
mg/dL
2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5x
upper limit of normal (ULN)
3. Total bilirubin ≤ 1.5 mg/dL, except in cases of Gilbert's syndrome
- Able to give informed consent. Subjects unable to give informed consent will not be
eligible for this study
Exclusion Criteria:
- Women who are pregnant or breastfeeding.
- Subjects with significant GI disease involvement by PET imaging
- In the investigator's judgment, have any medical condition likely to interfere with
assessment of safety or efficacy, be unable to tolerate additional radiation, or be
unlikely to complete all protocol-required visits and procedures.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Maria Iglesias
I'm interested
Dermatology Clinical Trials
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: [ 18F]F-AraG PET
Eligibility
Inclusion Criteria:
- Age ≥ 18 years old
- Histologically confirmed aggressive B cell NHL including the following types defined
by WHO 2008:
- DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma;
DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of
the elderly; OR
- primary mediastinal (thymic) large B cell lymphoma
- transformation of follicular lymphoma, marginal zone lymphoma or chronic
lymphocytic leukemia to DLBCL will also be included
- Measurable disease by PET imaging (as defined by Cheson (2014)), that meets all the
following criteria:
- At least one measureable lesion away from head & neck, liver, kidneys, GI tract
and bladder
- At least one biopsy-accessible lesion or lymph node.
- Express willingness to undergo low risk FNA or core biopsy of subcutaneous accessible
lesion or lymph node.
- Scheduled to receive commercial or research CAR T cell therapy with axicabtagene
ciloleucel (Yescarta ®) as part of anticancer therapy.
- Adequate renal and hepatic function, defined as:
1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min or Cr < 1.6
mg/dL
2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5x
upper limit of normal (ULN)
3. Total bilirubin ≤ 1.5 mg/dL, except in cases of Gilbert's syndrome
- Able to give informed consent. Subjects unable to give informed consent will not be
eligible for this study
Exclusion Criteria:
- Women who are pregnant or breastfeeding.
- Subjects with significant GI disease involvement by PET imaging
- In the investigator's judgment, have any medical condition likely to interfere with
assessment of safety or efficacy, be unable to tolerate additional radiation, or be
unlikely to complete all protocol-required visits and procedures.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Maria Iglesias
I'm interested
Pediatric Dermatology Clinical Trials
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: [ 18F]F-AraG PET
Eligibility
Inclusion Criteria:
- Age ≥ 18 years old
- Histologically confirmed aggressive B cell NHL including the following types defined
by WHO 2008:
- DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma;
DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of
the elderly; OR
- primary mediastinal (thymic) large B cell lymphoma
- transformation of follicular lymphoma, marginal zone lymphoma or chronic
lymphocytic leukemia to DLBCL will also be included
- Measurable disease by PET imaging (as defined by Cheson (2014)), that meets all the
following criteria:
- At least one measureable lesion away from head & neck, liver, kidneys, GI tract
and bladder
- At least one biopsy-accessible lesion or lymph node.
- Express willingness to undergo low risk FNA or core biopsy of subcutaneous accessible
lesion or lymph node.
- Scheduled to receive commercial or research CAR T cell therapy with axicabtagene
ciloleucel (Yescarta ®) as part of anticancer therapy.
- Adequate renal and hepatic function, defined as:
1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min or Cr < 1.6
mg/dL
2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5x
upper limit of normal (ULN)
3. Total bilirubin ≤ 1.5 mg/dL, except in cases of Gilbert's syndrome
- Able to give informed consent. Subjects unable to give informed consent will not be
eligible for this study
Exclusion Criteria:
- Women who are pregnant or breastfeeding.
- Subjects with significant GI disease involvement by PET imaging
- In the investigator's judgment, have any medical condition likely to interfere with
assessment of safety or efficacy, be unable to tolerate additional radiation, or be
unlikely to complete all protocol-required visits and procedures.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Maria Iglesias
I'm interested
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: [ 18F]F-AraG PET
Eligibility
Inclusion Criteria:
- Age ≥ 18 years old
- Histologically confirmed aggressive B cell NHL including the following types defined
by WHO 2008:
- DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma;
DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of
the elderly; OR
- primary mediastinal (thymic) large B cell lymphoma
- transformation of follicular lymphoma, marginal zone lymphoma or chronic
lymphocytic leukemia to DLBCL will also be included
- Measurable disease by PET imaging (as defined by Cheson (2014)), that meets all the
following criteria:
- At least one measureable lesion away from head & neck, liver, kidneys, GI tract
and bladder
- At least one biopsy-accessible lesion or lymph node.
- Express willingness to undergo low risk FNA or core biopsy of subcutaneous accessible
lesion or lymph node.
- Scheduled to receive commercial or research CAR T cell therapy with axicabtagene
ciloleucel (Yescarta ®) as part of anticancer therapy.
- Adequate renal and hepatic function, defined as:
1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min or Cr < 1.6
mg/dL
2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5x
upper limit of normal (ULN)
3. Total bilirubin ≤ 1.5 mg/dL, except in cases of Gilbert's syndrome
- Able to give informed consent. Subjects unable to give informed consent will not be
eligible for this study
Exclusion Criteria:
- Women who are pregnant or breastfeeding.
- Subjects with significant GI disease involvement by PET imaging
- In the investigator's judgment, have any medical condition likely to interfere with
assessment of safety or efficacy, be unable to tolerate additional radiation, or be
unlikely to complete all protocol-required visits and procedures.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Maria Iglesias
I'm interested
18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: [ 18F]F-AraG PET
Eligibility
Inclusion Criteria:
- Age ≥ 18 years old
- Histologically confirmed aggressive B cell NHL including the following types defined
by WHO 2008:
- DLBCL not otherwise specified; T cell/histiocyte rich large B cell lymphoma;
DLBCL associated with chronic inflammation; Epstein Barr virus (EBV)+ DLBCL of
the elderly; OR
- primary mediastinal (thymic) large B cell lymphoma
- transformation of follicular lymphoma, marginal zone lymphoma or chronic
lymphocytic leukemia to DLBCL will also be included
- Measurable disease by PET imaging (as defined by Cheson (2014)), that meets all the
following criteria:
- At least one measureable lesion away from head & neck, liver, kidneys, GI tract
and bladder
- At least one biopsy-accessible lesion or lymph node.
- Express willingness to undergo low risk FNA or core biopsy of subcutaneous accessible
lesion or lymph node.
- Scheduled to receive commercial or research CAR T cell therapy with axicabtagene
ciloleucel (Yescarta ®) as part of anticancer therapy.
- Adequate renal and hepatic function, defined as:
1. Creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 mL/min or Cr < 1.6
mg/dL
2. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 2.5x
upper limit of normal (ULN)
3. Total bilirubin ≤ 1.5 mg/dL, except in cases of Gilbert's syndrome
- Able to give informed consent. Subjects unable to give informed consent will not be
eligible for this study
Exclusion Criteria:
- Women who are pregnant or breastfeeding.
- Subjects with significant GI disease involvement by PET imaging
- In the investigator's judgment, have any medical condition likely to interfere with
assessment of safety or efficacy, be unable to tolerate additional radiation, or be
unlikely to complete all protocol-required visits and procedures.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Maria Iglesias
I'm interested